NCT01483729View on ClinicalTrials.gov

A Relative Bioavailability Study of Danoprevir and Ritonavir in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Healthy Volunteer
Interventions
DRUG

danoprevir

Phase 3 Tablet Formulation 1, single oral dose

DRUG

danoprevir

Phase 3 Tablet Formulation 2, single oral dose

DRUG

danoprevir

Reference Phase 2 Tablet Formulation, single oral dose

DRUG

ritonavir

Test Formulation 1, single oral dose

DRUG

ritonavir

Test Formulation 2, single oral dose

DRUG

ritonavir

Reference Formulation, single oral dose

Trial Locations (1)

8011

Christchurch

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01483729 - A Relative Bioavailability Study of Danoprevir and Ritonavir in Healthy Volunteers | Biotech Hunter | Biotech Hunter